Compare AbbVie Inc (ABBV) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Keysight Technologies Inc — how do they compare? AbbVie Inc trades at $252.81 (market cap $449.91B), while Keysight Technologies Inc trades at $315.94 (market cap $52.83B). The key difference: AbbVie Inc is far larger — about 8.5× Keysight Technologies Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| ABBV | KEYS | |
|---|---|---|
Market Cap | $449.91B | $52.83B |
Sector | Health | Technology |
52-Week High | $261.07 | $373.34 |
52-Week Low | $184.85 | $158.51 |
Enterprise Value | $513.38B | $53.17B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Keysight Technologies (KEYS) trades at $309.12, down 1.51% today, with a bearish technical signal despite strong earnings beats in recent quarters. The company maintains solid profitability with a 63.67% gross margin and 17.31% net margin, though valuation multiples like a P/E of 51.49 appear elevated. Recent news highlights strategic collaborations in 6G and photonics, positioning KEYS for growth in AI and wireless markets.
The outlook is mixed: analyst consensus is bullish with a $390.30 price target (75% buy ratings), but technical weakness and high valuation pose near-term risks. Upside hinges on execution in high-frequency RF and photonics markets, while downside risks include competitive pressures and integration challenges from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
